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Background: Emerging studies of human pluripotent stem cells (hPSCs) raise new prospects for neurodegenerative
disease modeling and cell replacement therapies. Therefore, understanding the mechanisms underlying the
commitment of neural progenitor cells (NPCs) is important for the application of hPSCs in neurodegenerative
disease therapies. It has been reported that epigenetic modifications of histones play important roles in neural
differentiation, but the exact mechanisms in regulating hPSC differentiation towards NPCs are not fully elucidated.
Results: We demonstrated that suppression of histone deacetylases (HDACs) promoted the differentiation of hPSCs
towards NPCs. Application of HDAC inhibitors (HDACi) increased the expression of neuroectodermal markers and
enhanced the neuroectodermal specification once neural differentiation was initiated, thereby leading to more NPC
generation. Similarly, the transcriptome analysis showed that HDACi increased the expression levels of ectodermal
markers and triggered the NPC differentiation related pathways, while decreasing the expression levels of
endodermal and mesodermal markers. Furthermore, we documented that HDAC3 but not HDAC1 or HDAC2 was
the critical regulator participating in NPC differentiation, and knockdown of HDAC3′s cofactor SMRT exhibited a
similar effect as HDAC3 on NPC generation.
Conclusions: Our study reveals that HDACs, especially HDAC3, negatively regulate the differentiation of hPSCs
towards NPCs at an earlier stage of neural differentiation. Moreover, HDAC3 might function by forming a repressor
complex with its cofactor SMRT during this process. Thus, our findings uncover an important epigenetic mechanism
of HDAC3 in the differentiation of hPSCs towards NPCs.
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Human pluripotent stem cellsBackground
Human pluripotent stem cells (hPSCs) including human
embryonic stem cells (hESCs) and human induced pluripo-
tent stem cells (hiPSCs) possess the potential to differenti-
ate into all cell types of three germ layers, which raises new
prospects for disease modeling, molecular mechanism find-
ing and cell-replacement therapies of neurodegenerative
diseases that have a very complex nature of pathogenesis* Correspondence: wdle@sibs.ac.cn
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unless otherwise stated.involving both neurons and glial cells [1-4]. The major chal-
lenge is how to efficiently generate renewable neural pro-
genitor cells (NPCs), which can be further differentiated
into neurons, astrocytes or oligodendrocytes under different
conditions, for the study of cell-autonomous or non-cell-
autonomous effects on disease development and cell
replacement therapy [5,6]. Therefore, exploring the me-
chanisms underlying NPC commitment during neural dif-
ferentiation will be of great importance.
It has been reported that multiple signaling pathways
are involved in neural induction from hPSCs. The retin-
oic acid (RA) signaling pathway works synergistically
with sonic hedgehog (SHH) and bone morphogenetic
proteins (BMPs) as well as fibroblast growth factors
(FGFs) signaling pathways to determine the extendingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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embryonic development [7]. RA is a critical morphogen
for the generation of NPCs [8,9]. In addition, specification
of ectoderm into neural cells and epidermal cells is di-
rected by Wnt, BMP and FGF pathways [10-12]. Blocking
the BMP/SMAD signaling pathway with small molecules
up-regulates the expression of neural transcription factors,
such as SOX2, PAX6 and NESTIN, and, therefore, facili-
tates NPC generation from hPSCs [13]. Moreover, FGF2
can antagonize BMP signaling to stabilize neural identity
during early neural specification [14].
Generally, neural differentiation of hPSCs consists of
two major processes: NPC generation from hPSCs and
final neuronal or glial conversion from the NPCs. Epigen-
etic modifications of DNA and histones play important
roles in the transcriptional regulation of neural cell fate-
specific genes [15,16]. Among those epigenetic processes,
histone deacetylases (HDACs) participate in neural differ-
entiation by modifying histone acetylation/deacetylation
levels. It has been reported that HDAC inhibitors (HDACi)
such as valproic acid (VPA), sodium butyrate (NaB) and
trichostatin A (TSA) can promote neuronal differentiation
of NSCs/NPCs isolated from adult mouse brain, while
suppressing their differentiation into oligodendrocytes and
astrocytes [17-19]. However, there is a somewhat contro-
versial report showing that deletion of the histone acetyl-
transferase (HAT) cofactor transformation/transcription
domain-associated protein (Trrap) can improve the differ-
entiation of NPCs into neurons in mice [20], implying that
disruption of the HAT recruitment can also enhance
neuronal differentiation. Thus, the mechanisms by which
histone acetylation or deacetylation affects neural differen-
tiation might be complicated. Moreover, those studies
mainly demonstrate that the process of neuron or glial cell
specification from NPCs, which is the latter process of
neural differentiation, can be modulated by HDACs. How-
ever, the potential roles of HDACs in the early stage of
neural differentiation in mediating hPSC differentiation to-
wards NPCs have yet to be determined.
Here we report that suppression of HDACs remarkably
enhances the generation of NPCs. We find that HDACi,
such as NaB and mocetinostat (MGCD0103, MGCD), can
promote neuroectodermal specification once the neural
differentiation is initiated. Furthermore, we document that
HDAC3 might negatively regulate NPC commitment by
forming a repressor complex with its cofactor SMRT (also
known as nuclear receptor corepressor 2, NCOR2); knock-
ing down of HDAC3 or SMRT in hPSCs exhibits similar
effects on the generation of NPCs. Collectively, our studies
uncover an important epigenetic mechanism of HDAC3
modification in the differentiation of hPSCs towards
NPCs, which may facilitate the establishment of an opti-
mized strategy of NPC generation from hPSCs for basic
science and application research.Results
HDACi promote the generation of NPCs
The H9 hESC line used in our study was in an undifferen-
tiated state. This cell line expressed pluripotent markers
SOX2 and OCT4 but not NPC markers NESTIN or PAX6
(see Additional file 1: Figure S1A). We initiated the neural
induction of H9 by RA treatment, followed by neuro-
sphere formation (Figure 1A). We found that many cells
died at the beginning of neurosphere formation. However,
nearly 95% of cells derived from neurospheres were NES-
TIN and SOX2 dual positive NPCs at the end of this stage
(Figure 1B), suggesting that the cells which finally contrib-
uted to NPC generation survived during the neurosphere
formation. Moreover, the NPCs could spontaneously dif-
ferentiate into neurons and glial cells in NPC medium
without bFGF (Figure 1C). These results suggest that typ-
ical NPCs with integrated differentiation potentials are
generated using this strategy. Therefore, we utilized this
model of neural differentiation to study the mechanisms
underlying the differentiation of hPSCs towards NPCs.
It is reported that retinoic acid receptors (RARs) recruit
HDACs to repress differentiation related genes [21], indi-
cating that histone deacetylation can regulate the RA sig-
naling pathway. Our results showed that transcripts of
class I and class II HDACs were increased once the differ-
entiation was initiated and were kept at high levels in all
stages, indicating that HDACs participate in the process of
neural differentiation (see Additional file 1: Figure S1B).
To investigate whether HDACs play roles in NPC gener-
ation, we suppressed histone deacetylation using several
HDACi. Of those, VPA (from 0.3 mM to 3 mM) and NaB
(from 50 μM to 1 mM) are pan-inhibitors of class I and
class II HDACs [17,22,23]. First, we treated H9 cells with
NaB and VPA at various concentrations for 24 hours to
evaluate the toxicity of those HDACi. We found that most
H9 cells changed their morphology and died when treated
with NaB at 0.5 mM to 5 mM or with VPA at 1 mM to
5 mM (see Additional file 2: Figure S2A). Therefore, we
chose 0.1 mM of NaB and 0.5 mM of VPA for our study.
We also applied tubastatin A (TubA) and PCI-34051
(PCI) at 5 μM, and MGCD at 0.5 μM, the concentrations
of which were shown to inhibit HDAC6 or HDAC8 or
HDAC1-3 without obvious cytotoxicity [24,25].
We then treated H9 cells with those HDACi with optimal
concentrations at the stage of RA induction. Interestingly,
we found that the number and size of the neurospheres
were significantly increased upon VPA, NaB or MGCD
treatment. However, we did not observe significant changes
in the PCI- or TubA-treated cells compared to the un-
treated cells (Figure 1D), suggesting that class I HDACs, es-
pecially HDAC1, HDAC2 and HDAC3, may play more
important roles than other HDACs in NPC generation.
As MGCD inhibited HDAC1, HDAC2 and HDAC3 in
a dose-dependent manner, we then tested the effects of
Figure 1 HDACi greatly enhance hPSCs differentiation towards NPCs. (A) Schematic representation of the neural differentiation in
monolayer culture. (B) Immunostaining of cells derived from neurospheres with antibodies against NESTIN (green) and SOX2 (red) and
quantification of NESTIN and SOX2 dual positive cells on day 18 of differentiation. The nuclei were stained by Hoechst. Scale bar, 50 μm. The inset
shows a higher magnification view. Scale bar, 100 μm. (C) Immunostaining of cells after 40 days of spontaneous differentiation with antibodies
against MAP2 (green) and GFAP (red). The nuclei were stained by Hoechst. Scale bar, 50 μm. The inset shows a higher magnification view. Scale
bar, 100 μm. (D) Neurospheres were formed after HDACi treatment for seven days. The sizes of neurospheres were analyzed on day 18 of
differentiation. Black arrows represent typical neurospheres, and red arrowheads represent cell debris. (E-G) Neurospheres were formed after
MGCD treatment for seven days and the diameters of the neurospheres were measured and quantified on day 18, respectively. (H-J)
Neurospheres were formed after NaB treatment for seven days or eighteen days and the diameters of the neurospheres were detected and
quantified on day 18 of differentiation, respectively. Scale bars, 200 μm. The error bars indicate SEM; ns, not significant; ***P <0.001; n >50.
(K) The efficiency of NPC generation was assessed by counting the number of cells derived from digested neurospheres on day 18. **P <0.01;
n >/=3. HDACi, HDAC inhibitors; hPSCs, human pluripotent stem cells; NPC, neural progenitor cell; SEM, standard error of the mean.
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that the neurospheres became larger as MGCD concen-
tration increased and about 90% of the neurospheres
were larger than 200 μm in diameter when MGCD was
used at 0.5 μM to 1.66 μM (Figure 1F and G).
To explore whether HDACi treatment affected the
growth of neurospheres, we continuously treated the
neurospheres with NaB at the second stage in which the
neurospheres were formed and grown (Figure 1H). We
observed that the neurospheres from 18-day-treatment
cells (18D-NaB) were comparable in size and number to
those from 7-day-treatment cells (7D-NaB). More than
70% of the neurospheres from both treatments were
larger than 200 μm, while more than 40% of the neuro-
spheres from control cells were smaller than 150 μm
(Figure 1I). Moreover, the average diameters of neu-
rospheres from 7D-NaB and 18D-NaB showed no sig-
nificant difference (Figure 1J), suggesting that NaB
treatment at the second stage does not change the
growth of neurospheres and persistent HDACi treatment
is unnecessary. In other words, HDACi may play a role
at the stage of RA induction but not at the stage of neu-
rosphere formation. In fact, we documented that incu-
bating with MGCD for only three days was sufficient to
enhance the NPC generation (see Additional file 2:
Figure S2B), suggesting that HDACi might promote the
NPC commitment at a very early time point of the NPC
differentiation.
Importantly, as the above neurosphere morphology
changes directly reflect the efficiency of NPC generation,
we determined the efficiency by calculating the number
of cells derived from neurospheres on day 18. The
neural differentiation of hPSCs with or without HDACi
treatment was initiated in 6-cm dishes with the same cell
number. At the end of the second stage, we found that
the number of NPCs derived from the neurospheres of
both NaB- and MGCD-treated cells was 10- to 15-fold
more than that of the control cells (Figure 1K). These
results indicate that suppression of HDACs by HDACi
can significantly enhance the differentiation of NPCs
from hESCs.
HDACi do not alter the properties of NPCs
We then attempted to identify whether the properties of
generated NPCs were influenced by the HDACi treat-
ment. We showed that about 95% of the neurosphere
cells from HDACi-treated cells were typical NPCs as de-
tected by NESTIN and SOX2 immunostaining, manifest-
ing no significant differences compared with control
cells (Figure 2A and B). Furthermore, we found that
NPCs could differentiate into mature neurons expressing
MAP2 and NeuN with comparable efficiencies (Figure 2C
and D), demonstrating that HDACi do not compromise
the neuronal differentiation potential of the generatedNPCs. Taken together, these results indicate that HDACs
function at the early stage of NPC differentiation from
hPSCs without affecting the integrity of neuronal differ-
entiation of the NPCs.
HDACi promote neuroectodermal specification
In order to explore the mechanisms of HDACs in NPC
generation, we focused on the first stage of differenti-
ation when hPSCs committed to different cell lineages.
We found that NaB and MGCD altered neither the pro-
liferation of cells (Figure 3A and B) nor cell survival
(Figure 3C and D). The cell number of HDACi-treated
cells was similar to that of untreated cells during differ-
entiation (Figure 3E), suggesting that cell growth during
differentiation is not affected by HDACi treatment.
To elucidate potential molecular networks regulated by
HDACs, we performed gene expression profiling of the
differentiating cells treated with MGCD on day 3 and day
7 (D3M and D7M), as well as the control cells at the same
time points of neural differentiation (D3C and D7C). A
total of 1,632 genes were differentially expressed between
the MGCD-treated group and the control group on day 3
of differentiation (D3M versus D3C), whereas at the end
of this stage, 2,475 genes were differentially expressed
(D7M versus D7C) (Figure 4A-C). Among them, we found
that 399 genes were differentially expressed consistently
from day 3 to day 7 after MGCD treatment (Figure 4C).
Gene ontology (GO) analysis of the overlapped genes
showed that the genes associated with organismal devel-
opment, cell differentiation and nervous system develop-
ment were significantly affected by MGCD treatment
during differentiation (Figure 4D). Furthermore, pathway
enrichment analysis of the overlapped genes revealed that
multiple signaling pathways relevant to neural differenti-
ation, such as phosphatidylinositol 3-kinase (PI3K)-Akt,
mitogen-activated protein kinase (MAPK) and Notch sig-
naling pathway, were significantly activated by MGCD
(Figure 4E).
From the results of both genome-wide expression ana-
lysis and real-time PCR, we found that compared with
undifferentiated H9, the transcripts of stemness markers
were decreased during differentiation, while the tran-
scripts of the markers of the three germ layers were in-
creased, suggesting that the cells with different fates
were specified from H9 after RA induction for seven
days (Figure 5A-C).
We assumed that suppression of histone deacetylation
might assist RA to induce H9 cells to differentiate to-
wards neuroectodermal cells during the first seven days.
Interestingly, NaB and MGCD treatment increased the
transcripts of the majority of neuroectodermal markers
(for example, PAX6), while it decreased the transcripts
of mesodermal and endodermal markers (for example,
GATA6) (Figure 5A-C). Noticeably, the transcript of
Figure 2 HDACi do not alter the properties of generated NPCs. (A) Neurospheres were digested and plated on dishes. NPCs were then
visualized using immunostaining with anti-NESTIN (green) and anti-SOX2 (red) antibodies. (B) The percentages of NPCs were calculated, the error
bars indicate SEM; n = 4. (C, D) NPCs were differentiated into neurons, which was detected by immunostaining with anti-MAP2 (green) and
anti-NeuN (red) antibodies after 50 days of differentiation. The efficiency of neuronal differentiation was compared among control cells and
HDACi treated cells. Scale bars, 50 μm. The error bars indicate SEM; n>/=3. HDACi, HDAC inhibitors; NPCs, neural progenitor cells; SEM, standard
error of the mean.
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reached a higher level with the addition of NaB or MGCD
(Figure 5B and C). Moreover, we analyzed the cells by im-
munostaining and flow cytometry with antibodies against
PAX6, SOX2 and NESTIN on day 7 of differentiation. We
found that the number of dual positive PAX6-SOX2 cells
or SOX2-NESTIN cells was significantly increased after
NaB and MGCD treatment at the end of the RA induction
stage (Figure 5D and E; Additional file 3: Figure S3). Simi-
larly, the protein levels of PAX6 and SOX2 in the HDACi-
treated cells were significantly higher than in the control
cells (Figure 5F-I), confirming that HDACi promote NPC
differentiation. These results indicate that HDACi might
promote neuroectodermal specification at the early stage of
differentiation.We then asked how NaB and MGCD enhanced neuroec-
todermal specification. It is known that HDACi can induce
hyperacetylation of histones by inhibiting histone deacetyla-
tion. We found that the acetylation levels of histone H3 at
lysine 9 (acH3K9) in the NaB- and MGCD-treated cells
were higher than that of the control cells on day 7 of dif-
ferentiation (Figure 5J and K). The increased expression
of neuroectodermal genes might be directly related to
acH3K9. We performed chromatin immunoprecipitation
(ChIP) and found that the binding of acetylated histone H3
with the promoter of PAX6 was significantly enhanced in
the NaB- and MGCD-treated cells, which may contribute
to the increased expression of PAX6 (Figure 5L).
Taken together, these results suggest that inhibiting
histone deacetylation by HDACi could promote the
Figure 3 Proliferation and apoptosis analysis. (A, B) The proliferation ability of H9 cells after HDACi treatment on day 3 of differentiation was
assessed by BrdU incorporation. The error bars indicate SEM; n>/=4. (C, D) The apoptosis of H9 cells after HDACi treatment on day 3 of differentiation
was detected by Annexin V/PI staining. The error bars indicate SEM, n = 4. (E) The cell number of H9 cells during differentiation after HDACi treatment
was counted. The error bars indicate SEM; n = 4. BrdU, bromodeoxyuridine; HDACi, HDAC inhibitors; SEM, standard error of the mean.
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and give rise to more cells with a neural cell lineage-fate
during RA treatment, thus generating more NPCs.
HDACi promote the differentiation of NPCs from hiPSCs
To investigate whether HDACs can regulate the differenti-
ation of NPCs from other hPSCs, we employed an hiPSC
line (named N-iPSC-1) which was kindly provided by Dr.
Ying Jin’s lab [26]. We found that NaB and MGCD also
enhanced the formation of neurospheres of N-iPSC-1
(Figure 6A). The neurospheres derived from HDACi treat-
ment were significantly larger than controls (Figure 6B
and C), and the histone acetylation levels of the HDACi-
treated cells were higher than that of the control cells on
day 7 of differentiation (Figure 6D). Meanwhile, there were
apparently more PAX6+, SOX2+ and NESTIN+ cells in theHDACi- treated cells (Figure 6E and F), indicating an in-
crease in conversion of neuroectodermal cells after HDAC
was inhibited. These results are consistent with those of
H9, confirming that inhibiting HDACs can promote differ-
entiation of NPCs not only from hESCs but also from
hiPSCs in a similar manner.
Knockdown of HDAC3 or SMRT enhances NPC generation
We then attempted to identify which HDAC critically func-
tioned in NPC generation. We knocked down HDAC1,
HDAC2 or HDAC3 individually by several short hairpin
RNA (shRNA) sequences and used one non-target shRNA
sequence as a negative control (shNC). We found that the
mRNA and protein levels of the HDACs were significantly
decreased in the transfected cells (Figure 7A; Additional
file 4: Figure S4A-S4D). Interestingly, knockdown of
Figure 4 (See legend on next page.)
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Figure 4 Gene-expression patterns and GO analysis in H9 cells with or without MGCD treatment. (A, B) Summary of the functional
categories of genes (A) and pathways (B) significantly enriched in response to MGCD treatment for seven days. Green bars represent the
proportion of genes involved in each category, red curve indicates statistical significance. (C) Venn diagram showing overlap of differentially
expressed genes from D7M versus D7C (orange circle) and D3M versus D3C (blue circle). (D, E) Summary of the functional categories of genes
(D) and pathways (E) enriched both in D7M versus D7C and D3M versus D3C groups. Green bars represent the proportion of genes involved in
each category. Red curve indicates statistical significance. GO, gene ontology.
Yang et al. BMC Biology 2014, 12:95 Page 8 of 17
http://www.biomedcentral.com/1741-7007/12/95HDAC3 but not HDAC1 or HDAC2 could enhance neu-
rosphere formation as MGCD treatment (Figure 7B). Al-
though HDAC1 and HDAC2 were also the targets of
MGCD, there was apparently more cell debris and fewer
neurospheres derived from H9-shHDAC1 cells or even
worse in H9-shHDAC2 cells. We observed that the tran-
script levels of PAX6 and SOX2 were down-regulated
whereas the GATA6 level was up-regulated after HDAC1
was suppressed, which is just the opposite of the results of
MGCD treatment (see Additional file 4: Figure S4E).
These results suggest that HDAC3 but not HDAC1 or
HDAC2 is the critical regulator that negatively regulates
NPC generation.
It has been demonstrated that HDACs execute their
functions by forming multiprotein complexes with their
cofactors. Generally, HDAC1 and HDAC2 are recruited to
the corepressors REST/CoREST while HDAC3 is re-
cruited to NCoR/SMRT. The complexes then bind to
sequence-specific DNA, which can condense the chroma-
tin structures and repress gene expression [27]. We dem-
onstrated that HDAC3 interacted with SMRT in H9 by
co-immunoprecipitation (Co-IP) assay (Figure 7C). We
speculated that HDAC3 might form this complex with
SMRT in the NPC commitment. To confirm this assump-
tion, we knocked down SMRT in H9 cells. The expression
of SMRT was down-regulated in undifferentiated H9 and
it remained lower in H9-shSMRT cells after seven days of
differentiation, as was the expression of HDAC3 in H9-
shHDAC3 cells (Figure 7D; Additional file 4: Figure S4F).
Excitingly, the number and size of neurospheres generated
from H9-shSMRT cell lines were comparable to those
from H9-shHDAC3 cell lines (The upper panels of
Figure 7E and F). Also, the expression levels of PAX6,
SOX2 and NESTIN were significantly higher in H9-
shHDAC3 (H9-shHDAC3-Con) and H9-shSMRT (H9-
shSMRT-Con) cells than in H9-shNC (H9-shNC-Con)
cells at the end of the first stage, which is consistent
with the results of MGCD treatment (H9-shNC-MGCD)
(Figure 7G and H; Additional file 4: Figure S4G). More-
over, upon MGCD treatment, H9-shHDAC3 cells and
H9-shSMRT cells showed a further increase in neuro-
sphere formation during differentiation (the lower panels
of Figure 7E and F) and an up-regulation in transcripts of
PAX6, SOX2 and NESTIN, but a down-regulation in
transcript of GATA6 (Figure 7G and H), implying that theinhibitor treatment and knockdown of the repressors
might have a synergistic effect on NPC generation.
We then asked whether knockdown of HDAC3 or
SMRT may alter the identity of H9. We found that the
profiles of SOX2 and OCT4 immunostaining in H9-
shHDAC3 or H9-shSMRT cells were similar to those in
H9-shNC (Additional file 4: Figure S4H). These results
suggest that suppression of HDAC3 or SMRT can en-
hance neuroectodermal specification without comprom-
ising the identity of hPSCs.
Overall, our study reveals that NPC specification from
hPSCs can be repressed by the complex of HDAC3 and
its co-repressor SMRT. During the process of neural dif-
ferentiation, the repression of neuroectodermal genes is
attenuated, which is accompanied by an increase in
acetylation of target genes (Figure 8). Furthermore, HDACi
treatment or knockdown of the repressors may further re-
duce this repression and then promote the hPSC differenti-
ation into NPCs (Figure 8).
Discussion
HDACs demonstrate very pleiotropic ability in stem cell
differentiation, including acting on NSC, hematopoietic
stem cell and cardiac stem cell differentiation [28-30].
Previous investigations reported that inhibiting HDACs
by HDACi could promote NSCs and NPCs to differenti-
ate into neuronal or glial cells [17,22,31,32]. However,
the commitment of NPCs from hPSCs and further dif-
ferentiation of NPCs into neuronal or glial cells are two
successive but different processes regulated by different
mechanisms [33-35].
Here we report that HDACs participate in the earlier
process of neural differentiation. It has been reported
that PAX6 and SOX2 control NPC identity [36-38], and
PAX6 is an important transcriptional determinant of hu-
man neuroectodermal cell fate; knockdown of PAX6
blocks neuroectodermal specification from hPSCs [39].
Thus, the up-regulation of PAX6 and SOX2 might ac-
count for the conversion of more cells with a neuroecto-
dermal fate. In addition, the down-regulated transcripts
of mesodermal and endodermal markers in HDACi-
treatment cells during the RA induction stage represent
a reduction of specification of mesoderm and endoderm
cells, which may lead to increased conversion of hPSCs
towards ectoderm cells. Together, the change of cell
Figure 5 (See legend on next page.)
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Figure 5 HDACi greatly promote neuroectodermal specification. (A) Heat map of normalized expression levels of the typical neuroectoderm,
mesoderm and endoderm genes which were differentially expressed after MGCD treatment for three days or seven days. Low expression levels
are indicated by green colors, and high expression levels are indicated by red colors. (B, C) On day 7 of differentiation, real-time PCR was performed to
determine the mRNA levels of typical genes for three germ layers after NaB or MGCD treatment for seven days. (D, E) On day 7, neuroectodermal cells
were visualized by immunostaining with antibodies against SOX2 (red) and PAX6 (green) (D) or SOX2 (red) and NESTIN (green) (E). Scale bars, 50 μm.
Higher magnification views are shown in the inset frames. Scale bars, 150 μm. (F-I) Protein levels of PAX6 and SOX2 were assessed by immunoblotting.
The density of the bands was analyzed by the Image J software and expressed as fold of control. (J, K) Acetylation levels of histone H3K9 were
detected by immunostaining (J) and immunoblotting (K), respectively. Higher magnification views are shown in the inset frames. Scale bars, 150 μm.
(L) H9 cells were cultured in the ESC medium with the addition of NaB or MGCD for seven days and immunoprecipitated with anti-acH3K9 antibody.
ChIP DNA levels of PAX6 were analyzed by semi-quantitative PCR. Scale bars, 50 μm. The error bars indicate SEM, *P <0.05; n >/=3. ChIP, chromatin
immunoprecipitation; HDACi, HDAC inhibitors; SEM, standard error of the mean.
Figure 6 HDACi enhance the NPC generation of hiPSCs. (A-C) Neurospheres were formed from the N-iPSC-1 cell line after HDACi treatment
and the diameters of the neurospheres were measured and quantified on day 18. The error bars indicate SEM, ***P <0.001; n >/=50. Black arrows
represent typical neurospheres and red arrowheads represent cell debris. (D) Acetylation levels of histone H3K9 in N-iPSC-1 cells were detected
by immunostaining on day 7 of differentiation. (E, F) Neuroectodermal cells were visualized by immunostaining with antibodies against PAX6
(green) and SOX2 (red) (E) or NESTIN (green) and SOX2 (red) (F) on day 7 of differentiation. Scale bars, 50 μm. HDACi, HDAC inhibitors; hiPSCs,
human induced pluripotent stem cells; SEM, standard error of the mean.
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Figure 7 (See legend on next page.)
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Figure 7 Knockdown of HDAC3 or SMRT enhances NPC generation. (A) Knockdown efficiency of shHDAC1 or shHDAC2, shHDAC3 was assessed
by real-time PCR. The error bars indicate SEM. **P <0.01; ***P <0.001. (B) Neurosphere formation of H9-shHDAC1 and H9-shHDAC2 cells as well as
H9-shHDAC3 cells were analyzed on day 18. Scale bar, 200 μm. Black arrows represent typical neurospheres, and red arrowheads represent cell debris.
(C) Co-IP of endogenous HDAC3 and SMRT from H9 cell lysate was performed with HDAC3 or SMRT antibodies. (D) Knockdown efficiency of SMRT
was assessed by real-time PCR. (E, F) On day 18 of differentiation, neurospheres were formed in shNC, shHDAC3 and shSMRT H9 cells with or without
MGCD treatment for seven days. Black arrows represent typical neurospheres, and red arrowheads represent cell debris. (G, H) On day 7 of differentiation,
real-time PCR was performed to determine the mRNA levels of neuroectodermal genes (PAX6, SOX2 and NESTIN) and endoderm gene (GATA6) in
shHDAC3 and shSMRT H9 cells with or without MGCD treatment for seven days. Scale bars, 200 μm. The error bars indicate SEM, *P <0.05; **P <0.01;
***P <0.001; n >/=3. Co-IP, co-immunoprecipitation; HDAC, histone deacetylase; NPC, neural progenitor cell; SEM, standard error of the mean.
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might be one of the reasons that lead to increased NPC
generation. However, there also exists another possibil-
ity that all PSCs are directed to differentiate to NPC
under the induction of RA. However, neural differ-
entiation is a dynamic process, and not all cells can dif-
ferentiate in a synchronous manner even under the
same neural differentiation condition [40,41]. Thus,
only parts of PSCs can finally commit to NPCs, while
many cells die at the beginning of neurosphere forma-
tion. Upon HDAC suppression, the expression levels of
NPC markers in all cells are increased, and, therefore,
cells are more prone to commit to NPCs under that dif-
ferentiation condition.
We observe that knockdown of HDAC3 in H9 cells
shows similar results with those of HDACi treatment,
whereas suppression of HDAC1 or HDAC2 fails to en-
hance the NPC specification. Indeed, there are appar-
ently more dead cells and fewer neurospheres derived
from H9-shHDAC1 and H9-shHDAC2 than from H9-
shNC during differentiation, suggesting that HDAC1 or
HDAC2 is more likely to function in cell survival or
other key cellular events. It has been reported that
HDAC1 deletion causes embryonic lethality before em-
bryonic day (E)10.5 in mice [42] and half of HDAC2-
null mice succumb by postnatal day 25 [43]. Moreover,Figure 8 Proposed model of enhanced NPC generation by inhibiting thconditional deletion of both HDAC1 and HDAC2 in
NSCs in mice results in severe brain abnormalities and
lethality at postnatal day 7 [44]. Previous studies also
showed that deleted HDAC3 could lead to deficiency in
neural crest development in mice [45], and activation of
HDAC3 could enhance endothelial cell differentiation
from ESCs [46]. It seems that HDACs have essential, but
redundant, functions during neural system development.
Robustly genetic loss of HDACs may block the process
of neural differentiation in mouse brain and lead to de-
velopmental defects, whereas inhibition of HDACs to
some extent could enhance the NPC commitment.
It is known that neuronal genes can be repressed by the
complexes of HDACs and their co-repressors in mouse
ESCs, NPCs and differentiated non-neuronal cells [47-49].
Here we report that individually knocking down any factor
of the HDAC3/SMRT complex can elevate the expressions
of neuroectodermal genes, indicating that HDAC3 might
negatively regulate the NPC commitment through the re-
pressor complex with SMRT. SMRT has been shown to
inhibit the Notch signaling pathway by repressing the
transcription of HES1 [50,51]. The whole-genome expres-
sion analysis in our study reveals that the Notch signaling
pathway is influenced by MGCD treatment. It is likely that
the HDAC3/SMRT complex regulates NPC generation by
modifying Notch signaling pathway. Future studies aree HDAC3/SMRT co-repressor complex. NPC, neural progenitor cell.
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of HDAC3/SMRT and how this complex regulates NPC
specification.
Furthermore, our findings may also facilitate the es-
tablishment of an optimized strategy of neural differen-
tiation from hPSCs for future studies. We are able to
enhance the generation of NPCs from hPSCs by 10- to
15-fold through the application of HDACi. Although
knockdown of HDAC3 or SMRT can promote NPC gener-
ation, pharmacological inhibition of HDACs is more prac-
tical for future clinical application. Importantly, HDACi
treatment other than knockdown of HDACs can keep gen-
etic fidelity of the cells during differentiation. The similar
outcomes from the hiPSC line, N-iPSC-1, show that the
initial epigenetic landscapes between H9 and N-iPSC-1, at
least the deacetylation landscapes for neural differentiation,
are very similar. It is believed that NPCs from patient-
specific iPSCs are better suited for the transplantation
treatment of multiple neurodegenerative diseases. Our
unpublished data show that the NPC generation of
Alzheimer’s disease (AD) patient-specific iPSCs can also be
enhanced by HDACi treatment. This might imply a
broader application of our findings in iPSCs derived from
patients with specific neurodegenerative diseases. There-
fore, our study may provide useful information for further
investigation of the molecular mechanisms underlying the
induction of specific NPCs from hPSCs and may facilitate
their application in NPC-transplantation therapies.
Conclusions
In summary, our findings demonstrate that HDACs, in
particular HDAC3, negatively regulate the differentiation
of NPCs from hPSCs. HDAC3 might orchestrate SMRT
to form a repressor complex, inhibition of which promotes
NPC specification. Taken together, our data provide a
novel regulatory epigenetic mechanism in governing the
differentiation of hPSCs towards NPCs.
Methods
Cell culture of hPSCs
Human ESCs H9 were purchased from WiCell (Madison,
WI, US) and human iPSCs (named N-iPSC-1) [26] were
provided by Dr. Ying Jin from the Institute of Health
Sciences, Shanghai Institutes for Biological Sciences.
Both cell lines were cultured in the mTeSR1 medium
(STEMCELL Technologies, Vancouver, BC, Canada) on
matrigel (BD, Franklin Lakes, NJ, USA) coated dishes. H9
and N-iPSC-1 lines with passage number P35 to P55 were
used in this study.
NPC generation and differentiation
Neural differentiation was induced by RA treatment. First,
a total 1 × 106 undifferentiated hPSCs split into small
clones by dispase (1 mg/ml, Millipore, Billerica, MA, USA)were cultured in mTeSR1 medium with 10 μM all-trans-
retinoic acid (Sigma, St.Louis, MO, USA) on a matrigel-
coated 6-cm dish. The cell numbers of the small clones
varied from about 340 to 870 cells (520 cells average) as we
show in Additional file 1: Figure S1A and Additional file 4:
Figure S4H. After seven days of RA treatment, the cells
were digested by dispase and gently pipetted into small
clumps, the sizes of which were comparable to the ESC
clones when we initiated neural differentiation. The cell
clumps were aggregated in knock-out serum replacement
(KSR) medium for four days, followed by culture in neuro-
sphere medium for seven more days to form neurospheres.
After that, neurospheres were digested into single cells by
accutase (STEMCELL Technologies), which can either be
maintained as NPCs in NPC medium or further be induced
to neurons or glia.
In some cases, HDACi was added to the mTeSR1 with
RA for a different number of days at the first stage. NaB
and VPA were purchased from Sigma; MGCD, TubA and
PCI were from Selleck Chemicals (Houston, TX, USA).
NPCs were spontaneously differentiated into neurons
or glia in NPC medium without bFGF. MAP2+ neurons
and GFAP+ glia could be detected after differentiated for
more than 35 days.
For neuronal differentiation with high efficiency, NPCs
were plated on poly-L-ornithine (PLO, 15 μg/ml, Sigma)/
Laminin (1 μg/ml, Sigma)-coated dishes at a density of
1 × 104 cells/cm2 in the neuronal differentiation medium
for neuron generation.
Medium for differentiation
KSR medium: (D)MEM/F12 medium with 20% KSR, 1%
GlutaMax-1, 1% non-essential amino acid (NEAA), 50 μM
β-mercaptoethanol (ME) and 1% penicillin/streptomycin
(P/S).
Neurosphere medium: (D)MEM/F12 medium containing
1% N2 supplement, 1% GlutaMax-1, 1% NEAA, 50 μM β-
ME, 1% P/S, 8 μg/ml heparin, 20 ng/ml bFGF and 20 ng/
ml epidermal growth factor (EGF).
NPC medium: (D)MEM/F12 and neurobasal medium
(1:1) containing 0.5% N2, 1% B27, 1% GlutaMax-1, 1%
NEAA, 50 μM β-ME, 1% P/S and 10 ng/ml bFGF.
Neuronal differentiation medium: neurobasal medium
containing 1% N2, 2% B27, 1% GlutaMax-1, 1% NEAA,
50 μM β-ME, 1% P/S, 20 ng/ml never growth factor (NGF),
20 ng/ml brain-derived neurotrophic factor (BDNF) and
20 ng/ml glial-eerived neurotrophic factor (GDNF).
The medium and supplements were from Invitrogen
(Carlsbad, NY, USA). All growth factors and cytokines were
from R&D (Minneapolis, MN, USA).
Clones and lentivirus packaging
Lentiviral vectors targeting human HDAC1, HDAC2
and HDAC3 were purchased from 3D-HTS company
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pLKO.1 lentiviral vector was employed to knockdown
human SMRT. Briefly, siRNA oligos targeting SMRT
were annealed and inserted into the AgeI and EcoRI
sites of the pLKO.1 vector. The targeted sequences of
SMRT were: 5′-GCT TCA CAA CAC AGG CAT GAA-
3′ and 5′-GCA GCG CAT CAA GTT CAT CAA-3′.
For packaging, 293FT cells were co-transfected with the
lentiviral vector and two helper plasmids pMD.G and
psPAX2 by calcium phosphate transfection according to
a previously described method [52,53]. The medium
was then replaced after overnight. The supernatant was
harvested 48 and 72 hours, respectively, after transfec-
tion and concentrated by precipitation with PEG-8000
(Sigma). The yielded lentivirus particles were then dis-
solved in PBS, aliquoted and frozen at −80°C until use.
Generally, every 10 ml of supernatant was finally con-
centrated into 50 μl as one aliquot.
Stably-transfected cell line screening
H9 cells were digested into single cells by accutase and
plated in 6-well-plates at a density of 1 × 106 cells/well in
mTeSR1 medium. After adherence, one aliquot of lentivirus
particles was applied to the cells for 24 hours. The medium
was then changed every day and Y-27632 (STEMCELL
Technologies) was added to the medium for the first two
days. After 72 hours, 0.5 μg/ml of puromycin (Millipore)
was used to select the transfected cells.
Gene expression
Total RNA was isolated from cultured cells using TRIzol
(Invitrogen) and was reverse-transcripted into cDNA
using a ReverTra Ace qPCR RT Kit (Toyobo, Osaka,
Japan). Real-time PCR was then performed using a SYBR
premix Ex TaqTM II kit (Takara, Shiga, Japan) and carried
out on a real-time PCR System (ABI 7500). All primers
were verified by melting curve analyses containing a single
melt curve peak. Primer information is listed in Additional
file 5: Table S1. The relative expression level of each gene
was analyzed using the 2-ΔΔCt algorithm normalizing to
GAPDH and relative to the control samples.
Flow cytometry analysis
For flow cytometry analysis of NPCs, cells of the neuro-
spheres derived from H9 were fixed by 4% paraformalde-
hyde (PFA) for 10 minutes, and then blocked in PBS with
0.5% BSA and 0.1% Triton X-100 for 30 minutes. After
that, cells were stained by Alexa fluor-647 mouse anti-
NESTIN (1:500, BD), Alexa fluor-488 mouse anti-SOX2
(1:100, BD) or PerCP-Cy™ 5.5 mouse anti-human PAX6
(1:50, BD) for one hour. Finally, NPCs were washed twice
with PBS and then suspended in 200 μl of PBS for flow cy-
tometry analysis (BD FACSAria).The proliferation ability was measured by flow cytometry
analysis. Cells from H9 on day 3 of differentiation were in-
corporated with BrdU (1:100, Sigma) in a cell incubator for
30 minutes and digested into single cells for fixation in 4%
PFA for 10 minutes, and then treated with 2 M HCL for
30 minutes at 37°C, followed by Alexa-fluor-647 mouse-
anti-BrdU (1:100, Sigma) staining as described above.
The number of apoptotic cells were measured using an
Annexin V apoptosis detection kit by flow cytometry ac-
cording to the manufacturer’s instructions (eBioscience,
San Diego, CA, USA).
Immunoblotting
Total proteins were extracted from cultured cells using
radioimmunoprecipitation assay (RIPA) lysis buffer
(Beyotime, Jiangsu, China) and 30 μg proteins were then
loaded and separated by SDS-PAGE gels, followed by
transfer onto polyvinylidene fluoride (PVDF) membranes,
and incubation of the membranes with 5% nonfat milk for
one hour at room temperature to block nonspecific sites.
After that, the membranes were incubated overnight at
4°C with the following primary antibodies: H3 (1:2,000;
Cell Signaling, Danvers, MA, USA), acH3K9 (1:1,000; Cell
Signaling), PAX6 (1:1,000; Millipore), SOX2 (1:1,000; Cell
Signaling), HDAC1 (1:1,000; Cell Signaling), HDAC3
(1:1,000; Cell Signaling), SMRT (1:100, Sigma) and β-actin
(1:30,000; Sigma). The membranes were then washed with
PBS and incubated with horseradish peroxidase (HRP)
conjugated secondary antibodies (1:2,000; Cell Signaling)
at room temperature for two hours. The signals were
finally detected using a SuperSignal Detection Kit (Pierce,
Rockford, IL, USA) according to the manufacturer’s
instructions.
Immunostaining
To perform immunofluorescent staining, cells from hPSCs
during differentiation plated on the glass coverslips were
fixed in 4% PFA for 15 minutes at room temperature. After
washing, the fixed cells were incubated with blocking buffer
(PBS containing 3% goat serum and 0.3% Triton X-100) for
30 minutes at room temperature, followed by an overnight
incubation at 4°C with the following primary antibodies:
OCT4 (1:400, Cell Signaling), PAX6 (1:400; Millipore),
SOX2 (1:400; Cell Signaling), NESTIN (1:800; Millipore),
MAP2 (1:1 000; Sigma), NeuN (1:500; Millipore) and Ac-
H3K9 (1:400; Cell Signaling). After repeated washes, the
cells were incubated with secondary antibodies conjugated
with Alexa fluor-488/555 (1:400; Invitrogen) at room
temperature for two hours. The nuclei were finally stained
with Hoechst 33342 (Beyotime) before observation under
microscopy (Olympus). For quantitative analysis, the per-
centage of NPCs or neurons was calculated by the number
of NESTIN+ or NeuN+ cells versus the number of
Hoechst+ cells. For each treated group, more than three
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counted, and the results were determined from more than
four independent experiments.
Chromatin immunoprecipitation assay
A ChIP assay was carried out using a Pierce Agarose
ChIP Kit according to the manufacturer’s instructions
(Thermo Scientific, Rockford, IL, USA). Briefly, 2 × 106
cells were cross-linked in 1% (w/v) formaldehyde for
10 minutes at room temperature and inactivated by the
addition of glycine. Cells were then washed and har-
vested into tubes by scraping before centrifugation. After
that, cell pellets were lysed and the nuclei were digested
with Micrococcal Nuclease. The sheared chromatin ex-
tracts were immunoprecipitated with anti-acH3K9 (1:50;
Cell Signaling) antibody at 4°C overnight, followed by in-
cubation with A/G plus agarose resin. The binding DNA
was then recovered after incubation at 65°C and purified
as templates for semi-quantitative PCR. The primers
specific to the PAX6 promoter are listed in Additional
file 5: Table S1.
Co-immunoprecipitation assay
For validation of the interaction between HDAC3 and
SMRT, H9 cells were digested by IP lysis buffer (Beyotime)
with 1% PMSF and the cell extracts were pre-cleared by
incubating with 20 μl protein A/G agarose (Santa Cruz,
Dallas, TX, USA) at 4°C for 30 minutes and the super-
natant was transferred to new 1.5 ml tubes. Then the pre-
cleared cell extracts were incubated with 1 μg HDAC3
antibody (Cell Signaling), 2 μg SMRT antibody (Santa
Cruz) or 1 μg rabbit IgG (Cell signaling), respectively, at
4°C for two hours. Immunocomplexes were then cross-
linked with 30 μl protein A/G agarose at 4°C overnight.
The tubes were spun and the bound proteins (immuno-
precipitates) were washed five times with IP lysis buffer
containing 1% PMSF at 4°C, and eluted from beads by in-
cubation with 1 × SDS protein loading buffer. Input and IP
protein samples were analyzed by immunoblotting.
Microarray analysis
A total of five mRNA samples were prepared for whole-
genome microarray (Affymetrix U133 plus 2.0 gene chips)
analysis at the Shanghai Biotechnology Corporation.
Among these samples, one was undifferentiated H9 cells
(D0), two were the control H9 cells on day 3 and day 7 of
neural differentiation (D3C and D7C), and another two
were MGCD-treated H9 cells at the two time points of
neural differentiation (D3M and D7M). Global differen-
tially expressed genes between control cells and MGCD-
treated cells from each day of differentiation were analyzed
by GO analysis and pathway enrichment analysis as previ-
ously described [54]. We have deposited our raw micro-
array data and the results of differentially expressed genes,GO analysis as well as pathway enrichment analysis in the
Gene Expression Omnibus (GEO) of the National Center
for Biotechnology Information [55] with GEO accession
number GSE61050.
Statistical analysis
All values are presented as the mean ± SEM values from
more than three independent experiments. Statistical sig-
nificance was determined using student’s t-test by Graph-
Pad Prism. The results were considered significant when
the P-value was less than 0.05.
Additional files
Additional file 1: Figure S1. HDACs participate in the process of neural
differentiation. (A) Immunostaining of undifferentiated H9 cells with
antibody against OCT4 (green), SOX2 (red), NESTIN (red) and PAX6 (red).
Scale bar, 50 μm. (B) The mRNA expressions of class I and class II HDACs
during neural differentiation were determined by real-time PCR. The error
bars indicate SEM.
Additional file 2: Figure S2. Concentrations of NaB and VPA and
time-dependent manner of MGCD. (A) The morphology of H9 cells was
observed after treatment with various concentrations of NaB or VPA.
(B) Neurospheres were formed from H9 cells that were induced for
neural differentiation with the addition of MGCD for two, three, four and
five days, respectively. Scale bar, 200 μm.
Additional file 3: Figure S3. Flow cytometry analysis of the cells on
day 7 of differentiation. (A, B) PAX6 and SOX2 dual positive cells were
analyzed and quantified by FC. The error bars indicate SEM, ***P <0.001;
n = 3. (C, D) NESTIN and SOX2 dual positive cells were analyzed and
quantified by flow cytometry. The error bars indicate SEM, ***P <0.001;
n = 4.
Additional file 4: Figure S4. Neurosphere formation and stemness after
HDAC or SMRT suppression. (A-D) Knockdown efficiency of HDAC1 or
HDAC3 was determined by western blot. The density of the bands was
analyzed using Image J software and expressed as fold of control. (E) The
transcripts of PAX6, SOX2, NESTIN and GATA6 in H9-shHDAC1 cells on day
7 of differentiation. (F) Expression of HDAC3 or SMRT in H9-shHDAC3 or
H9-shSMRT on day 7 of differentiation. (G) Protein levels of PAX6 and SOX2
were assessed by western blot in shHDAC3 cells with or without MGCD
treatment on day 7 of differentiation. (H) Stemness of undifferentiated
H9-shHDAC3 or H9-shSMRT cells was detected by immunostaining with
anti-OCT4 (green) and anti-SOX2 (red) antibodies. Scale bar, 50 μm. The error
bars indicate SEM. *P <0.05; **P <0.01; ***P <0.001; n>/=3.
Additional file 5: Table S1. A list of primers used for real-time PCR and
ChIP analysis.
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